For a person with type 2 diabetes, the numbers on a glucose meter are only part of the worry. The bigger fear is the heart. This week the US Food and Drug Administration gave those patients something concrete: it approved tirzepatide, Eli Lilly’s Mounjaro, to reduce major adverse cardiovascular events in adults with type 2 diabetes.
What the approval means
The drug is now formally recognized for lowering the risk of cardiovascular death, nonfatal heart attack and nonfatal stroke. It is the first dual GIP/GLP-1 receptor agonist to earn that label. The decision rests on SURPASS-CVOT, a head-to-head cardiovascular outcomes trial in which tirzepatide cut the risk of major cardiovascular events compared with existing therapy.
That matters because heart disease remains the leading cause of death for people with type 2 diabetes. Diabetes care has been drifting for years from a narrow focus on HbA1c toward protecting the kidneys, the heart and survival itself. Glucose control is necessary, the thinking now goes, but it is not enough.
Fewer injections, less fatigue
Coverage of the approval also pointed to a practical gain. It describes a once-weekly option that can cut how often some patients must inject. Tirzepatide is not insulin, but the point stands. Anyone who has lived with chronic disease knows how treatment fatigue wears people down, and a lighter routine can help them keep going with it. Fewer injections tend to mean better adherence, especially for people already juggling several medicines and regular monitoring.
Tirzepatide is also an established treatment for moderate-to-severe obstructive sleep apnea in adults with obesity, as diatribe.org notes.
A wider picture from Kidney Week
The same conversation played out at Kidney Week 2026, where a meta-analysis looked at SGLT2 inhibitors, another class that protects the heart and kidneys. It pooled 14 placebo-controlled randomized trials covering 76,969 patients. The combined risk of first hospitalization for heart failure or cardiovascular death fell 23 percent, and major adverse cardiovascular events dropped 14 percent. Kidney outcomes improved by 31 percent.
Yet a separate Kidney Week analysis found that more than half of patients with diabetic chronic kidney disease received neither an SGLT2 inhibitor nor some of the newer protective agents. Pharmacists, speakers said, can help close that gap through dosing decisions and therapy selection.
If you live with type 2 diabetes and wonder where these options fit in your own care, talk to your doctor. A new indication is only useful once it reaches the people who need it.
Sources
- Tirzepatide Approved to Reduce Cardiovascular Risk in People With Type 2 Diabetes | GreaterGood
- SGLT2 Inhibitors Confer Cardiorenal Protection | Metabolic Care Today
- 7 Surprising Benefits of GLP-1s Beyond Blood Sugar
Photo: Cheung Yin / Unsplash (Unsplash License)
